Type 2 Diabetes Market Dynamics Report Now Available
Posted on: Wednesday, 19 March 2008, 09:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c86360) has announced the addition of new Decision Resources report "Type 2 Diabetes Market Dynamics: Impact of Januvia and Other DPP-IV Inhibitors" to their offering.
Despite the variety of efficacious oral antidiabetics available to treat type 2 diabetes--many of them available generically--the unmet need in this disease remains high. In October 2006, the launch of Merck's Januvia (sitagliptin) introduced to the U.S. market the newest class of agents to treat this disease, the dipeptidyl peptidase-IV (DPP-IV) inhibitors, which enjoy several advantages over their competitors. Decision Resources reviews current and emerging treatment options for type 2 diabetes and examine the market, providing data on the uptake of novel branded agents over the last five years. We focus particularly on Januvia, its current clinical trial data, and its market uptake since launch; on Novartis's Galvus and Takeda's alogliptin, likely to be Januvia's most direct competitor; and on the market outlook for the DPP-IV inhibitor class.
Get the Answers You Need to Shape Your Strategy
The high level of unmet needs in type 2 diabetes offers significant opportunity for novel agents even at premium prices and despite generic competition. What are the greatest unmet needs in treatment of type 2 diabetes? Are any emerging therapies likely to fulfill these needs? What benefits do current therapies offer diabetic patients, and what are their drawbacks? Why will metformin continue to be physicians' first choice for first-line therapy?
The DPP-IV inhibitors offer several advantages over currently available therapies for type 2 diabetes. In what way are they superior to existing therapies? What unmet needs can these agents fulfill? What drawbacks may hinder physician uptake of the DPP-IV inhibitors? How are physicians likely to use these agents? Will they supplant any of the current leading therapies? Which companies are leading the development of DPP-IV inhibitors? What is the market outlook for the DPP-IV inhibitors?
Scope
- Current therapies, type 2 diabetes: Metformin (biguanide), sulfonylureas, peroxisome proliferator-activated receptor-gamma agonists (Actos, Avandia), glucagon-like peptide-1 analogues (Byetta), advantages, drawbacks, physician preferences.
- Type 2 diabetes market: 2007 sales and prescriptions, market leaders, uptake of emerging agents.
- Dipeptidyl peptidase-IV (DPP-IV) inhibitors: Januvia (sitagliptin, Merck), Galvus (vildagliptin, Novartis), alogliptin (Takeda), and saxagliptin (BMS, AstraZeneca), mechanism of action, clinical trials data, market uptake, sales and prescriptions, market outlook. Galvus (vildagliptin, Novartis)-- estimated launch date, clinical trials data. Market outlook for DPP-IV inhibitors.
Contents:
Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Current Treatments for Type 2 Diabetes
Metformin
Sulfonylureas
Peroxisome Proliferator-Activated Receptor-Gamma Agonists
Glucagon-Like Peptide-1 Analogues
The Type 2 Diabetes Market
2007 Sales and Prescriptions
Uptake of New Agents in the Type 2 Diabetes Market
PPAR-? Agonists
Byetta
Januvia--First in Class
Mechanism of Action
Clinical Trial Results
Januvia's Uptake in the Market
Emerging Competition
Novartis's Galvus
Takeda's Alogliptin
Bristol-Myers Squibb/AstraZeneca's Saxagliptin
Early-Stage DPP-IV Inhibitors
Outlook for DPP-IV Inhibitors
Tables:
1. Worldwide Sales of Agents Commonly Prescribed to Treat Type 2 Diabetes, 2007
2. Emerging Glucagon-Like Peptide 1 Analogues and Peroxisome Proliferator-Activated
Receptor Agonists
3. Physiological Functions of the Incretins GLP-1 and GIP
Figures:
1. Typical Decision Tree for Type 2 Diabetes, 2008
2. Market Share of Drug Classes to Treat Type 2 Diabetes, 2007
3. Sales of Newly Launched Agents to Treat Type 2 Diabetes, 2000-2006
4. Volume Share of Drug Classes Used to Treat Type 2 Diabetes, First Half of 2007
5. U.S. Sales of Januvia by Quarter, 2006-2007
For more information visit http://www.researchandmarkets.com/reports/c86360
Source: Business Wire
Related Articles
- Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013
- Activx Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes
- Healthnostics and GMD Addressing the Expanding $92 Billion Diabetic Supply Market
- Arisaph Pharmaceuticals Announces Results of Its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
- Takeda's Investigational DPP-4 Inhibitor Demonstrated Efficacy in Reducing Glucose Levels in Early Phase Study
- FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
- South Korea Diabetes Diagnostic Market Shows Immense Growth Potential
- Largely Untapped Potential Drives Future Growth of Chinese Diabetes Diagnostics Markets
- FDA Approves Once-Daily JANUVIA(TM), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes
- JANUVIA(TM) (Sitagliptin Phosphate) Receives Approval In Mexico; Approval of JANUVIA in Mexico Marks the First DPP-4 Inhibitor, a New Class of Oral Type 2 Diabetes Medicines, To Be Approved in the World
 |
 |
User Comments (0)
RSS Feeds